Please sign in to follow a disease.
New trial aims to slash deadly complications in Kids' stem cell transplants
NCT ID NCT07679100
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This trial tests multiple new treatments to improve outcomes for children receiving a stem cell transplant. It includes children from 1 week to 18 years old who are getting a transplant. The goal is to reduce serious complications like organ failure and infections, and make transplants safer and more effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- multiple interventions (to be added over time)
- What this could lead to
- If successful, this trial could identify better ways to manage stem cell transplants in children, reducing severe complications and improving survival and quality of life.
- What could go wrong
- This is an early-stage platform trial testing many interventions; results may take years and some interventions may prove ineffective or have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 10,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2027
An estimate. Start dates often move.
- Expected to finish
-
Dec 2047
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 week to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged \>1 week to ≤ 18 years old * The participant is intending to receive or will be eligible for allogeneic HSCT within the next 4 months. Exclusion Criteria: * Death is deemed to be imminent and inevitable AND one or more of the participant or parent/substitute decision maker, or attending physician are not committed to full active treatment * A suitable donor for HCT is not identified. Each domain may have additional, domain-specific eligibility criteria. The additional eligibility criteria that are specific to a domain will be provided in each domain-specific Study Record, linked to this Master record. Participants who fulfil the BANDICOOT Platform Eligibility Criteria will be assessed for enrolment into all domains that are active at their trial site.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Haematopoietic stem cell transplant, allogeneic are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.